United States Skin Cancer Therapeutics Market By Cancer Type (Melanoma, Non-melanoma, Others), By Type (Diagnosis, {Dermatoscopy, Biopsy, Genetic Tests, Others}, Therapeutics {Chemotherapy, Immunotherapy, Targeted Therapy, Others}), By Region, Competition Forecast & Opportunities, 2028
Published on: 2024-11-15 | No of Pages : 320 | Industry : Healthcare
Publisher : MIR | Format : PDF&Excel
United States Skin Cancer Therapeutics Market By Cancer Type (Melanoma, Non-melanoma, Others), By Type (Diagnosis, {Dermatoscopy, Biopsy, Genetic Tests, Others}, Therapeutics {Chemotherapy, Immunotherapy, Targeted Therapy, Others}), By Region, Competition Forecast & Opportunities, 2028
Forecast Period | 2024-2028 |
Market Size (2022) | USD 2.85 billion |
CAGR (2023-2028) | 7.24% |
Fastest Growing Segment | Melanoma |
Largest Market | Mid-West |
Market Overview
Key Market Drivers
Rising Cases of Skin Cancer
Advancements in Treatment Modalities
Rising Early Detection and Diagnosis
Increasing Immunotherapy Demand
Key Market Challenges
Late-Stage Diagnosis
Lack of Access to Specialized Care
High Treatment Costs
Key Market Trends
Advancements in Treatment Procedures
Clinical Trials and Research Investment
Segmental Insights
Cancer Type Insights
In 2022, the Skin Cancer Therapeutics Market was dominated by the
Type Insights
In 2022, the Skin Cancer Therapeutics Market was dominated by the Diagnosis segment and is predicted to continue expanding over the coming years.
Regional Insights
In 2022, the United States Skin Cancer Therapeutics Market was dominated by the Mid-West segment and is predicted to continue expanding over the coming years.
Recent Development
- In March 2022 , Nivolumab andrelatlimab-rmbw (Opdualag, Bristol-Myers Squibb Company) were approved by theUS FDA for adult and paediatric patients 12 years of age or older withunresectable or metastatic melanoma. Future market growth is probably beingdriven by the increasing approval of novel immunotherapies.
- In April 2022, A complete dealfor Regeneron Pharmaceuticals, Inc. to acquire Checkmate by CheckmatePharmaceuticals, Inc. was signed. With this acquisition, Regeneron hopes toadvance the main candidate Vidutolimod, which is presently being researched inconjunction with other drugs for the treatment of head and neck cancer,non-melanoma skin cancers, and melanoma.
Key Market Players
- AbbottLaboratories
- Amgen,Inc.
- PfizerInc.
- Bristol-MyersSquibb Company
- F.Hoffmann-La Roche Ltd
- Merck& Co., Inc.
- SanofiS.A.
- SunPharmaceutical Industries Ltd
- DaiichiSankyo Company, Limited
- Sirnaomics,Inc.
By Cancer Type | By Type | By Region |
|
|
|